Zobrazeno 1 - 10
of 55
pro vyhledávání: '"David W Kang"'
Autor:
David W. Kang, Renee Tannenbaum
'ENHANZE® drug delivery technology: Advancing subcutaneous drug delivery using recombinant human hyaluronidase PH20'provides readers with in-depth information on the potential benefits and challenges of subcutaneous (SC) drug delivery, the biology o
Publikováno v:
Drug Delivery, Vol 30, Iss 1 (2023)
AbstractSubcutaneous (SC) infusion of large volumes at rapid flow rates has historically been limited by the glycosaminoglycan hyaluronan (HA), which forms a barrier to bulk fluid flow in the SC space. Recombinant human hyaluronidase PH20 (rHuPH20) d
Externí odkaz:
https://doaj.org/article/49d3a4a1a47840febc5260a5eca0a60b
Autor:
Lavinia Morosi, Marina Meroni, Paolo Ubezio, Ilaria Fuso Nerini, Lucia Minoli, Luca Porcu, Nicolò Panini, Marika Colombo, Barbara Blouw, David W. Kang, Enrico Davoli, Massimo Zucchetti, Maurizio D’Incalci, Roberta Frapolli
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-13 (2021)
Abstract Background Scarce drug penetration in solid tumours is one of the possible causes of the limited efficacy of chemotherapy and is related to the altered tumour microenvironment. The abnormal tumour extracellular matrix (ECM) together with abn
Externí odkaz:
https://doaj.org/article/4214b5ab153e4739bc53c7865dca3750
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 3, Pp 503-513 (2020)
Abstract Introduction There is currently no consensus in the literature concerning the impact of aging on the properties of hyaluronan (HA) in the subcutaneous (SC) space. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates SC administration o
Externí odkaz:
https://doaj.org/article/c223b4dc9f09491eb56f35542dcfc11e
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0254765 (2021)
BackgroundRecombinant human hyaluronidase PH20 (rHuPH20) facilitates the dispersion and absorption of subcutaneously administered therapeutic agents. This study aimed to characterize the transient, local action of rHuPH20 in the subcutaneous (SC) spa
Externí odkaz:
https://doaj.org/article/c07c075fe3a34b4e935d5c8b108458aa
Autor:
Marie A. Printz, BA, Samuel S. Dychter, MD, Emanuel P. DeNoia, MD, Rena Harrigan, MPH, Barry J. Sugarman, PhD, Monica Zepeda, PhD, Jennifer Souratha, BSc, David W. Kang, BSc, Daniel C. Maneval, PhD
Publikováno v:
Current Therapeutic Research, Vol 93, Iss , Pp 100604- (2020)
ABSTRACT: Background: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/
Externí odkaz:
https://doaj.org/article/9727f714ed4549758640d27883f0f639
Publikováno v:
Expert Opinion on Drug Delivery. 18:1673-1685
The glycosaminoglycan hyaluronan forms a gel-like substance, which presents a barrier to bulk fluid flow in the subcutaneous (SC) space, limiting SC drug delivery volume and administration rates. Recombinant human hyaluronidase PH20 (rHuPH20) acts lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a3a052337437e2b10c0a9b988904921
https://doi.org/10.1080/17425247.2021.1981286
https://doi.org/10.1080/17425247.2021.1981286
Autor:
Marie A, Printz, Barry J, Sugarman, Rudolph D, Paladini, Michael C, Jorge, Yan, Wang, David W, Kang, Daniel C, Maneval, Michael J, LaBarre
Publikováno v:
The AAPS Journal. 24
Multiple FDA-approved and clinical-development stage therapeutics include recombinant human hyaluronidase PH20 (rHuPH20) to facilitate subcutaneous administration. As rHuPH20-reactive antibodies potentially interact with endogenous PH20, we investiga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dd987b0d5a8918688ebd6fcb24885b1
https://doi.org/10.1208/s12248-022-00757-3
https://doi.org/10.1208/s12248-022-00757-3
Autor:
Cameron J. Nowell, Daniel H.S. Brundel, Lisa M. Kaminskas, Gracia Gracia, Orlagh M. Feeney, Christopher J.H. Porter, Michelle M. McIntosh, David W. Kang, Estelle J.A. Suys
Publikováno v:
Nanomedicine. 16:275-292
Aim: Delivery of nanoparticles (NPs) to tumors can be impeded by high levels of hyaluronan (HA) in the stroma. Enzymatic depolymerization of HA with PEGylated hyaluronidase (PEGPH20) improves the delivery of antibodies to tumors. However, it is unkno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d58a79faf1ed4ce52d5c4edfebf9ae
https://doi.org/10.2217/nnm-2020-0433
https://doi.org/10.2217/nnm-2020-0433
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 3, Pp 503-513 (2020)
Dermatology and Therapy
Dermatology and Therapy
Introduction There is currently no consensus in the literature concerning the impact of aging on the properties of hyaluronan (HA) in the subcutaneous (SC) space. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates SC administration of injecte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7f49be4c5c5f6b3ef484c6eb72bdc53
https://doaj.org/article/c223b4dc9f09491eb56f35542dcfc11e
https://doaj.org/article/c223b4dc9f09491eb56f35542dcfc11e